Prostate Cancer International is
for 2011 by Great NonProfits
The U.S. Preventive Services Task Force (USPSTF) — after previously stating that it would be releasing its new recommendations about PSA testing for risk of prostate cancer on Tuesday next week — has been pressured (by a variety of organizations, and by the media) to release its draft recommendation today.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, PSA, risk, testing, USPSTF | 14 Comments »
Back in 2006 a report from a research team in the Tyrol, Austria, suggested that the availability of free PSA testing for prostate cancer risk had lowered the risk of prostate cancer mortality in the Tyrol as compared to all other areas of Austria. This original study is discussed elsewhere on this web site.
Filed under: Diagnosis, Management, Risk | Tagged: mortality, PSA, screening, testing, Tyrol | 5 Comments »
The full text of a recent article having the above title offers a good (if perhaps not perfect), reasonably current overview of issues related to PSA testing for prostate cancer and appeared recently in a supplement to the Canadian Journal of Urology.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Management, outcome, PSA, testing | 1 Comment »
The heading above is the first part of the title of a paper to be presented by Lilja et al. at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The data from this study needs to be seen in conjunction with data presented just the other day by Vickers.
Filed under: Diagnosis, Management, Prevention, Risk | Tagged: Management, PSA, rational, risk, screening, strategy, testing | 11 Comments »
It is becoming increasingly clear that the prevention, treatment, and management of prostate cancer is at an intellectual as well as a practical, clinical crossroads.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: dutasteride, finasteride, Prevention, PSA, screening, supplement, testing, testosterone | 2 Comments »
A report in Family Medicine gives us some insight into the views of primary care physicians (PCPs) with respect to PSA testing for prostate cancer risk and the appropriate roles of the patient and the physician in the decision to have or not have PSA tests.
Filed under: Diagnosis, Risk | Tagged: decision-making, patient, physician, PSA, screening, shared, testing | Leave a Comment »
A recently published study reports on the incidence of PSA testing in the United Kingdom (UK) in 2007. There is no national recommendation for prostate cancer testing (i.e., “screening”) in the UK. However, PSA testing is covered by National Health Service; men who request a PSA test will normally be given one by their family doctor.
Filed under: Diagnosis, Risk | Tagged: risk, screening, testing, UK | 1 Comment »
On March 29 we commented on a newly published paper by Drazer et al. dealing with prostate cancer testing in men of 70 years of age and older. Now this same issue has been taken up by Gina Kolata in an article in the New York Times that will certainly have wider reach than our [...]
Filed under: Diagnosis, Risk | Tagged: age, risk, screening, testing | 2 Comments »
The Cochrane reviews are widely considered to be among the most rigorous, systematic, and objective reviews of data related to specific medical topics. An initial Cochrane review of data on screening for prostate cancer was carried out in 2006, and it was updated in June 2009.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, mortality, PSA, risk, screeing, testing | 2 Comments »
The roles and behaviors of primary care physicians (PCPs) in the US in encouraging men to or discouraging men from having a PSA test to assess possible risk for prostate cancer are still not well understood.
Filed under: Diagnosis, Risk | Tagged: PCP, primary care, PSA, screening, testing | 6 Comments »
A report in New Zealand’s Old Dominion Post would appear to typify a classic type of sad over-reaction to the results of the recent Norrkoping screening study (on which we commented last week).
Filed under: Diagnosis, Risk | Tagged: New Zealand, PSA, screening, testing | 4 Comments »
A new report in the Journal of Clinical Oncology suggests that — at least between 2000 and 2005 — “excessive PSA screening in elderly men with limited life expectancies” was a significant problem, and may remain so today.
Filed under: Diagnosis, Risk | Tagged: age, life expectancy, PSA, screening, testing | 2 Comments »
Apparently, in the USA, there has been a small decrease in the incidence of PSA testing since the publication of data from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) and European Randomized Study of Screening for Prostate Cancer (ERSCP) trials back in March 2009.
Filed under: Diagnosis, Risk | Tagged: PSA, screening, testing | 4 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site